Clinical Trial

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2025 (before its estimated July 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibodies in diagnosis and screening of HER2-positive cancer patients.
Trial Details
NCT Number NCT07023861
Lead Sponsor Affiliated Hospital of Jiangnan University
Conditions Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
Enrollment 20 participants
Start Date 2025-07-01
Primary Completion 2026-07-07 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-17